You take a look at the presentation material and the "funnel" they provide for those markets. The number of applicable patients is the one at the bottom, not the total number of people with vitiligo. And then the number of people in that group who might decide to under go a dermabrasion operation (or several) and use Recell as part of the treatment will only be a fraction of those. And its still has to compete against existing treatments that have similar outcomes.
So I wouldn't bet on it producing spectacular revenue growth anytime soon. Whether or not it can help heal chronic ulcers remains to be proven, and how durable the healing might be is open to question.
Ann: JP Morgan Healthcare Conference Presentation, page-9
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.65 |
Change
-0.050(1.85%) |
Mkt cap ! $183.5M | |||
| Open | High | Low | Value | Volume |
| $2.64 | $2.68 | $2.63 | $283.6K | 107.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2206 | $2.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.67 | 5477 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVH (ASX) Chart |